Literature DB >> 15692239

Gene-gene and gene-environment interactions in mild hyperhomocysteinemia.

Armando D'Angelo1, Giuseppina Mazzola, Isabella Fermo.   

Abstract

Mild/moderate hyperhomocysteinemia (HHcy), a highly prevalent condition, is independently associated with an increased risk of arterial and venous thromboembolic diseases. Early reports of the association of mild/moderate HHcy with juvenile venous thromboembolism have shown familiarity for HHcy in relatives of index cases with thrombosis. Similar to inherited thrombophilia defects, inheritance of the HHcy phenotype was accordingly retained important for the definition of HHcy as an independent risk factor for thrombosis. A number of common polymorphisms in genes coding for methylenetetrahydrofolate reductase(MTHFR), methionine-synthase, methionine-synthase reductase and cysthationine beta-synthase (CBS) have been explored for their association with homocysteine levels, fasting and post-methionine load, and with thrombotic diseases. MTHFR thermolability accounts for a 10-fold increase in the risk of mild/moderate HHcy. With the possible exception of the CBS844ins68 insertion, there is no evidence for an increased risk of HHcy for any of these polymorphisms, isolated or in association with MTHFR thermolability. Environmental factors and MTHFR thermolability are main determinants of the HHcy phenotype.If mild/moderate HHcy is a pathogenetic risk factor for thrombosis, intervention aimed to improve the vitamin status appears of major importance, irrespective of common gene polymorphisms of the homocysteine metabolism.

Entities:  

Mesh:

Year:  2003        PMID: 15692239     DOI: 10.1159/000083824

Source DB:  PubMed          Journal:  Pathophysiol Haemost Thromb        ISSN: 1424-8832


  5 in total

1.  Gender and single nucleotide polymorphisms in MTHFR, BHMT, SPTLC1, CRBP2, CETP, and SCARB1 are significant predictors of plasma homocysteine normalized by RBC folate in healthy adults.

Authors:  Andrew J Clifford; Kehui Chen; Laura McWade; Gonzalo Rincon; Seung-Hyun Kim; Dirk M Holstege; Janel E Owens; Bitao Liu; Hans-Georg Müller; Juan F Medrano; James G Fadel; Alanna J Moshfegh; David J Baer; Janet A Novotny
Journal:  J Nutr       Date:  2012-07-25       Impact factor: 4.798

2.  Homocysteine and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in Tunisian patients with severe coronary artery disease.

Authors:  Lakhdar Ghazouani; Nesrine Abboud; Nabil Mtiraoui; Walid Zammiti; Faouzi Addad; Haitham Amin; Wassim Y Almawi; Touhami Mahjoub
Journal:  J Thromb Thrombolysis       Date:  2008-01-19       Impact factor: 2.300

3.  Identification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study.

Authors:  Anders Mälarstig; Alfonso Buil; Juan Carolos Souto; Robert Clarke; Francisco Blanco-Vaca; Jordi Fontcuberta; John Peden; Malin Andersen; Angela Silveira; Simona Barlera; Udo Seedorf; Hugh Watkins; Laura Almasy; Anders Hamsten; José Manuel Soria
Journal:  Blood       Date:  2009-06-12       Impact factor: 22.113

4.  Genetic variants modify the associations of concentrations of methylmalonic acid, vitamin B-12, vitamin B-6, and folate with bone mineral density.

Authors:  Ching-Ti Liu; David Karasik; Hanfei Xu; Yanhua Zhou; Kerry Broe; L Adrienne Cupples; Lisette Cpgm de Groot; Annelies Ham; Marian T Hannan; Yi-Hsiang Hsu; Paul Jacques; Robert R McLean; Ligi Paul; Jacob Selhub; Katerina Trajanoska; Nathalie van der Velde; Natasja van Schoor; Douglas P Kiel
Journal:  Am J Clin Nutr       Date:  2021-08-02       Impact factor: 8.472

5.  Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and L-Dopa Treatment.

Authors:  Agata Rozycka; Pawel P Jagodzinski; Wojciech Kozubski; Margarita Lianeri; Jolanta Dorszewska
Journal:  Curr Genomics       Date:  2013-12       Impact factor: 2.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.